Lisanti Capital Growth’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-78,425
Closed -$7.03M 149
2023
Q3
$7.03M Buy
+78,425
New +$7M 1.11% 33
2023
Q2
Sell
-57,275
Closed -$4.74M 155
2023
Q1
$4.74M Sell
57,275
-40,245
-41% -$3.26M 0.66% 65
2022
Q4
$7.67M Buy
+97,520
New +$7.84M 1.05% 38
2019
Q4
Sell
-53,385
Closed -$6.73M 122
2019
Q3
$6.73M Buy
+53,385
New +$6.78M 2.2% 9
2019
Q1
Sell
-46,765
Closed -$4.68M 120
2018
Q4
$4.68M Buy
46,765
+22,645
+94% +$2.38M 1.89% 11
2018
Q3
$2.76M Buy
+24,120
New +$2.5M 0.96% 47

Other funds holding HAE

Lisanti Capital Growth's HAE Position: Q4 2023 in Review

Lisanti Capital Growth sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 78,425 shares — an estimated $7.03M sold.

Lisanti Capital Growth first reported a position in HAE in Q3 2018 and held it in 6 quarters. The position peaked at $7.67M in Q4 2022. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

  • Lisanti Capital Growth reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
  • Lisanti Capital Growth sold 78,425 Haemonetics shares in Q4 2023, an estimated $7.03M.
  • Lisanti Capital Growth first reported a position in Haemonetics in Q3 2018 and held it in 6 quarters.
  • Lisanti Capital Growth's Haemonetics position peaked at $7.67M in Q4 2022.
  • 295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on Lisanti Capital Growth's 13F filing for Q4 2023, filed 6 Feb 2024.